Rationale: Physiological hypertrophy in the developing heart has been considered the product of an increase in volume of preexisting fetal cardiomyocytes in the absence of myocyte formation. Objective: In this study, we tested whether the mouse heart at birth has a pool of cardiac stem cells (CSCs) that differentiate into myocytes contributing to the postnatal expansion of the parenchymal cell compartment. Methods and Results: We have found that the newborn heart contains a population of c-kit-positive CSCs that are lineage negative, self-renewing, and multipotent. CSCs express the Notch1 receptor and show the nuclear localization of its active fragment, N1ICD. In 60% of cases, N1ICD was coupled with the presence of Nkx2.5, indicating that the commitment of CSCs to the myocyte lineage is regulated by Notch1. Importantly, overexpression of N1ICD in neonatal CSCs significantly expanded the proportion of transit-amplifying myocytes.
A t birth, the myocardium must accommodate the abrupt changes in the patterns of blood flow and circulatory resistance and the increasing demands of the rapidly growing organism. Physiological hypertrophy in the developing heart has been considered the result of an increase in volume of preexisting fetal cardiomyocytes, whereas the contribution of new myocytes to the postnatal expansion in ventricular mass was viewed as negligible at best. 1 However, the documentation of high levels of DNA synthesis in myocytes together with apoptotic cell death 2 indicate that the postnatal maturation of the heart is a complex process in which cardiomyogenesis may play a critical role in the acquisition of the adult heart phenotype.
By viral tagging and clonal marking, we have shown that cardiomyogenesis in the adult mouse heart depends on the activation and differentiation of a pool of cardiac stem cells (CSCs) that express the c-kit antigen. 3 On the basis of these findings, the question can be raised whether primitive cells with similar properties are present in the neonatal heart and the generation of new myocytes is dictated by lineage commitment of these cells. According to the traditional model of growth in self-renewing organs, stem cells give rise to progenitorprecursor cells, which then become highly dividing amplifying cells that eventually reach terminal differentiation and growth arrest. 4 This hierarchically structured mechanism of parenchymal cell generation may account for the expansion in myocyte number and volume of the neonatal heart. CSC-derived amplifying myocytes replicate and concurrently differentiate, mimicking cellular hyperplasia and hypertrophy. 5 The possibility exists that the formation of new myocytes mediated by CSC growth is not a minor phenomenon that undergoes sudden downregulation at birth, but it represents a continuous process that conditions the acquisition of the adult heart phenotype structurally and functionally. Activation of the Notch1 receptor is the critical determinant of the transition of CSCs to the compartment of amplifying myocytes and inhibition of this pathway has dramatic negative conse-quences on the adaptation of the heart to ischemic myocardial injury. 5 Collectively, these observations suggest that a similar mechanism may be operative in the developing heart, and Notch1 signaling modulates CSC differentiation and the formation of functionally competent myocytes.
Methods
The number of c-kit-positive CSCs and the number and volume of myocytes together with capillary density were evaluated quantitatively in neonatal mice in the absence and presence of ␥-secretase inhibition, which blocks Notch receptor function. Protocols are described in the expanded Methods section, available in the Online Data Supplement at http://circres.ahajournals.org.
Results

CSCs in the Neonatal Heart
The neonatal mouse heart at 3 to 7 days after birth was characterized by closely packed cardiomyocytes and capillary profiles (Online Figure I) . CSCs were clustered in atrial and ventricular niches and scattered throughout the myocardium ( Figure 1A and cytoplasmic markers documented a lineage relationship between CSCs and myocyte formation. Replicating myocytes were negative for c-kit and positive for Ki67 and phospho-H3. Cytokinesis was detected by the expression of Aurora B kinase, 6 which phosphorylates histone H3 and is required for cell division ( Figure 1E and 1F and Figure 2 ). Importantly, 83Ϯ12% of Ki67-positive myocytes expressed Nkx2.5 (Online Figure I) . c-kit-positive CSCs were isolated, expanded, and characterized by FACS (Online Figure II) . CSCs were negative for transcription factors and cytoplasmic proteins specific of myocytes (GATA4, Nkx2.5, MEF2C, and ␣-SA), endothelial cells (ECs: Ets1, flk1, and von Willebrand factor), and smooth muscle cells (SMCs: GATA6, ␣-SMA). They were also negative for markers of hematopoietic cells (CD34, CD45, and prominin/CD133). The absence of CD45 excluded the contribution of mast cells and the lack of CD34, CD45, prominin, and flk1 excluded bone marrow-derived endothelial progenitor cells (EPCs). Similarly, coronary vascular progenitor cells are flk1-positive 7 and did not contribute significantly to the CSC pool. Lineage negative CSCs exposed to differentiating medium lost c-kit and gave rise to myocytes, ECs, and SMCs; myocytes constituted the predominant pool. The commitment of CSCs to cardiomyocytes in vitro involved the expression of the same transcription factors (Nkx2.5, MEF2C) and contractile proteins (␣-SA) identified in vivo (Online Figure III) , suggesting that the acquisition of the myocyte phenotype in vitro recapitulated the in vivo differentiation program. Some forming myocytes acquired the electric characteristics of ventricular cells with fast Na ϩ current or displayed sinoatrial node-like properties with spontaneous action potentials ( Figure 3A and 3B). Thus, the developing mouse heart has CSCs that are self-renewing and multipotent.
Notch1 Receptor Function in Neonatal CSCs
Early after birth, 58Ϯ18% of CSCs expressed the Notch1 receptor ( Figure 3C and 3D); Notch2-4 receptors were detected in significantly smaller fractions of CSCs (Online Figure IV) . The membrane-bound Notch1 ligand, Jagged1, was distributed on the sarcolemma of cardiomyocytes and was always found at the interface between these cells and CSCs ( Figure 3E Figure 3E and 3F), the Notch1 intracellular domain (N1ICD). In contrast, the Delta-like 4 ligand was distributed predominantly in coronary vessels. 5 In 60% of cases, the presence of N1ICD in CSCs was associated with the nuclear expression of the early myocyte transcription factor Nkx2.5 (Online Figure IV) , raising the possibility that Notch1 favors the commitment of CSCs to the myocyte lineage. A causal relationship between N1ICD and the transactivation of Nkx2.5 in CSCs has previously been shown in the adult infarcted mouse heart. 5 Additionally, the presence of c-kit alone or Nkx2.5 did not preclude cell replication (Online Figure V) .
To establish whether Notch1 activation in neonatal CSCs plays a critical role in the formation of myocytes, CSCs harvested from newborn mice were transduced with a lentivirus carrying N1ICD and characterized 5 and 10 days later (Online Figure VI) . Potential target genes of Notch1 were evaluated by quantitative RT-PCR. With respect to control cells infected with a lentivirus carrying EGFP only, N1ICD overexpression upregulated the downstream effectors of the Depolarizing steps to Ϫ40 mV and ϩ10 mV reveal the lack of the fast Na ϩ current (I Na ) and the presence of Ca 2ϩ current (I Ca ), respectively (A). Action potentials in a ventricular-like CSC-derived myocyte stimulated at 1 and 2 Hz. Depolarizing steps activate both I Na and I Ca (B). C and D, Left ventricular (LV) myocardium at 6 days after birth in which the CSCs included in the squares are shown at higher magnification in the adjacent panels. CSCs are positive for c-kit (green) and Notch1 (red). E and F, c-kit-positive CSCs (arrows) are in contact with myocytes and Jagged1 is distributed at the interface between cardiomyocytes and CSCs (insets, arrowheads). N1ICD (yellow dots) is present in CSC nuclei.
Notch pathway Hes1, Hey1, and Hey2 together with the target gene Nkx2.5 ( Figure 4A ; Online Figure VI ). Transcripts of SRF remained relatively constant. Myocardin mRNA increased, whereas GATA4 decreased. The SMC and EC markers GATA6, Vezf1, and PECAM were downregulated. The transcriptional repression of GATA4 and GATA6 is consistent with the presence of several binding sites for Hes1 and Hey1 in the promoter region of all members of the GATA family. 8 The enhanced expression of myocardin paralleled the upregulation of Nkx2.5, which is a powerful transactivator of the myocardin promoter. 9 The physical interaction of myocardin with the DNA binding domain of GATA4 has a synergistic effect on the Nkx2.5 enhancer domain favoring myocyte hypertrophy. 10 This cellular response may require the downregulation of Notch1 signaling, which is involved in the early commitment of CSCs and the formation of cycling immature myocytes.
At 5 days, lentiviral infection with N1ICD resulted in a 3.4-fold increase in the number of CSCs expressing Nkx2.5 protein ( Figure 4B ). Essentially all N1ICD/c-myc-tag-positive cells showed Nkx2.5, indicating that Notch1 signaling was a crucial modulator of Nkx2.5 expression ( Figure 4C ; Online Figure VII ). Thus, Notch1 activation was characterized by CSC commitment with the acquisition of the early immature myocyte phenotype; 65% of these cells retained their replicative potential and were positive for the cell cycle marker Ki67 (Online Figure  VII) . Cycling cells positive for N1ICD and Nkx2.5 exhibited a thin layer of sarcomeric proteins typical of transit amplifying cells ( Figure 4C and 4D). At 10 days, CSCs overexpressing N1ICD maintained a poorly developed cell phenotype: They expressed Nkx2.5, were cycling, and could be passaged. Conversely, control cells increased in size, rarely were Nkx2.5positive, and showed enhanced accumulation of contractile proteins ( Figure 4E and 4F). Cell apoptosis was not affected by N1ICD overexpression (Online Figure VII) .
Collectively, these observations suggest that the Notch1 receptor is a major regulator of the early differentiation of neonatal CSCs and their transition to amplifying myocytes. The question was then whether a similar mechanism of myocyte generation was operative in vivo and contributed to postnatal myocardial growth.
Notch1 and Myocardial Growth
The in vitro results support the notion that the expression of Notch1 receptor on the plasma membrane of CSCs is linked to a permissive state in which the multipotentiality of CSCs is preserved. Conversely, the translocation of N1ICD to the nucleus leads to the preferential commitment of CSCs to the myocyte lineage with the acquisition of the amplifying state. This control of myocyte growth offered the opportunity to determine whether CSCs and the Notch1 pathway are involved directly in the formation of myocytes after birth, contributing to physiological cardiac hypertrophy.
The increase in myocardial mass after birth can occur by 4 mechanisms: (1) hypertrophy of the cardiomyocytes formed in prenatal life; (2) proliferation and hypertrophy of cardiomyocytes present at birth; (3) generation of new cardiomyocytes by activation and commitment of resident CSCs; and (4) a combination of these cellular processes. Scenarios 1 and 2 do not require the involvement of CSCs.
At birth, Notch1 was detected in CSCs, whereas cardiomyocytes did not express the extracellular domain of Notch1 or other Notch isoforms (Online Figure VIII ; see also Figure  3C and 3D; Online Figure IV ). In view of this differential distribution of Notch1 in CSCs and myocytes, stimuli activating or inhibiting Notch1 signaling exclusively affect primitive cells and do not affect preexisting myocytes. The presence of N1ICD in myocyte nuclei was by necessity restricted to parenchymal cells derived from CSC differentiation. Thus, to determine whether Notch1 activation in CSCs was an important variable of postnatal myocardial growth with the formation of a large myocyte progeny, the Notch system was inhibited in newborn mice for a period of 5 to 7 days.
Notch receptor function was markedly attenuated by administration of a ␥-secretase inhibitor, which opposed the translocation of N1ICD to the nucleus and the initiation of transcription of Notch-dependent genes. 5 The 5-to 7-day interval was chosen because this phase of cardiac development is characterized by a substantial increase in work load on the myocardium and maximum increase in heart weightto-body weight ratio. However, the ␥-secretase inhibitor may affect Notch-independent pathways, imposing a cautious interpretation of the collected results. Unfortunately, inducible cardiomyocyte-specific N1ICD-null mice would not clarify the role of CSCs during physiological hypertrophy after birth because Notch1 deletion would affect cells distal to CSCs. Similarly, the use of a c-kit promoter to target Notch1 in CSCs would involve c-kit-positive cells in multiple organs obscuring its effects on the heart.
If CSC-mediated myocyte formation is required in postnatal myocardial growth, a potential reduction in cardiomyogenesis may result in severe alterations in ventricular anatomy and function. In comparison with control animals injected with DMSO, mice exposed to the ␥-secretase inhibitor diluted in DMSO showed on echocardiography a reduction in fractional shortening and ejection fraction together with ventricular dilation and relative wall thinning ( Figure 5A through 5C; Online Movies I and II). Five of the 37 mice injected with the vehicle died over a period of 7 days. After treatment with the ␥-secretase inhibitor, the rate of animal mortality increased 3.3-fold, from 13% to 43%; 34 of the 79 treated mice died during this interval ( Figure 5D ). The high mortality rate of mice receiving DMSO was related to its unspecific toxic effects and was consistent with previous reports. 11 Although we did not establish the cause of death in these mice, echocardiographic measurements performed at 3, 5, and 7 days did not show cardiac alterations characteristic of a lethal myopathy (Online Figure IX) . In this regard, no further animal death was observed over a period of 2 weeks after suspension of DMSO administration. Conversely, mice exposed to the ␥-secretase inhibitor continued to die after cessation of treatment (see below).
In all animals, echocardiographic data were complemented with morphometric measurements in tissue sections, which allowed the computation of chamber volume and wall thickness at a uniform sarcomere length of 2.2 m. This approach was used because of the inevitable limitations inherent in echocardiography of the neonatal mouse heart and the impossibility to define with precision end-diastole and endsystole. The anatomic results strengthened the in vivo observations, documenting a striking degree of ventricular dilation and thinning of the wall with ␥-secretase inhibition ( Figure  5E and 5F). Thus, alterations in Notch receptor function in newborns lead to a dilated myopathy that develops rapidly and results in high animal mortality rates, emphasizing the importance of Notch signaling in the physiological maturation of the heart.
Notch Inhibition and Cardiomyogenesis
To assess the functional role of N1ICD in the generation of cardiomyocytes from activation and commitment of CSCs, the coexpression of c-kit, N1ICD, and Nkx2.5 was determined. These markers together with the presence of sarcomeric proteins identify the pool of myocyte progenitors-precursors in the myocardium. Amplifying myocytes represent the subsequent downstream step of the differentiation program; they are cycling c-kit-negative cells that contain transcription factors and cytoplasmic structures typical of maturing cells. 3, 5, 12 Because myocytes do not have the Notch1 extracellular domain, N1ICD in their nuclei demonstrates their origin from Notch1-positive CSCs.
During embryonic development from E10 to the end of gestation, Ϸ55% of myocyte nuclei expressed N1ICD and Nkx2.5, and this value decreased to Ϸ30% at birth ( Figure  6A through 6D) . The colocalization of N1ICD and Nkx2.5 in myocyte nuclei was confirmed by spectral analysis (Online Figure X) . The progressive decline in the fraction of N1ICDpositive myocytes was paralleled by a comparable reduction in the number of cells expressing Nkx2.5, which comprised Ϸ30% of myocytes at birth ( Figure 6E ). This value diminishes further in the adult myocardium, where the presence of Nkx2.5 is restricted to newly formed small myocytes derived from the differentiation of Notch1-positive CSCs. 5 In newborns, myocytes negative for N1ICD were larger and contained greater amounts of sarcomeric proteins ( Figure 6F ).
At completion of ␥-secretase inhibition, 1 week after birth, the fraction of c-kit-positive N1ICD-positive cells, including CSCs and myocyte progenitors-precursors, decreased 45% ( Figure 7A through 7C ). The number of Nkx2.5-positive early committed CSCs was severely affected, resulting in a dramatic attenuation in the pool of cells potentially responsible for cardiomyogenesis. Ki67-positive and N1ICD-positive myocytes were reduced by 62% and 66%, respectively ( Figure 7D through 7H). Hes1 and Nkx2.5 were also downregulated ( Figure 7I ). Thus, inactivation of the homeostatic control of cardiac growth by blockade of the proteolytic cleavage of Notch1 interfered with myocyte formation, favoring the structural and functional manifestations of a dilated myopathy.
Notch Inhibition and Physiological Hypertrophy
The postnatal expansion in cardiac mass is accomplished by increases in wall thickness and chamber diameter, which reflect the adaptation of the myocardium to the increases in 
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pressure and volume loads on the developing heart. The gross morphological indices of ventricular dimensions, wall thickness, and chamber diameter are the expression of a combination of parameters that includes (1) number of myocytes across the wall;
(2) average myocyte cross sectional diameter and length; and (3) the volume composition of the myocardium. Interference with CSC activation by ␥-secretase inhibition affected the formation of a myocyte progeny, leading to a dilated myopathy with disproportionate increase in left ventricular chamber volume (see Figure 5 ). Attenuation in the generation of cardiomyocytes led to a reduction of heart weight. Decreased left ventricular weight was dictated by a 54% smaller number of cardiomyocytes that were 55% larger ( Figure 8A ). Cell apoptosis was comparable in control and treated mice at 3 and 7 days (Online Figure XI) , excluding that cell death had a major impact on cardiac pathology and ventricular dysfunction. Importantly, the number of lineage-negative CSCs decreased 30% in treated mice (Online Figure XI) , indicating that the primary cause of the dilated cardiomyopathy was related to loss and defective differentiation of resident stem cells.
The hypertrophic response of the remaining myocytes was unable to compensate for the effect on myocyte formation. Myocyte hypertrophy was mostly mediated by cell lengthening, with little change in cell diameter. As a consequence, wall thinning was produced by a decrease in the mural number of cardiomyocytes, whereas cell lengthening was implicated in the expansion of cavitary volume ( Figure 8B) . Conversely, the number of capillary profiles per millimeter squared of myocardium did not decrease as a result of myocyte hypertrophy, suggesting that the coronary vasculature grew in proportion to the increase in myocyte size ( Figure 8B ). Although Ϸ10% of ECs expressed the Notch1 receptor in control and treated mice, ␥-secretase inhibition did not affect their proliferation rate measured by Ki67 labeling (Online Figure XI) . Collectively, these data indicate that defects in myocyte formation in combination with disproportionate cell lengthening promote alterations in ventricular anatomy, favoring the transition from physiological to pathological hypertrophy early in the maturation of the mouse heart.
Evolution of Postnatal Myocardial Growth
An important question concerned the reversibility of the dilated myopathy and the recovery of the functional and structural integrity of the myocardium. In rodents, myocyte formation and hypertrophy are dramatically enhanced during postnatal maturation up to the time of weaning, decreasing considerably thereafter. To establish the consequences of Notch inhibition during the first week of life on the subsequent growth of the heart and organism well-being, animal mortality was evaluated for an additional 2 weeks. Moreover, the characteristics of the heart in terms of cardiac anatomy, myocyte size, and number and extent of cell replication were determined at this interval together with the analysis of echocardiographic parameters.
The first week after cessation of ␥-secretase inhibition, 11 of the 31 treated animals died, whereas only 1 of the remaining 20 mice did not survive the subsequent week. These data suggest that the effects of Notch blockade began to fade away Ϸ7 days after the last administration of the drug. Conversely, only 1 of the 18 control mice injected with DMSO died during the same interval ( Figure 8C ). These striking changes in the survival of treated mice at 3 weeks were characterized by restoration of fractional shortening, ejection fraction, and cardiac size measured echocardiographically ( Figure 8D ). Anatomically, wall thickness and chamber volume returned to almost normal values. This structural recovery was mediated by myocyte hypertrophy and a significant increase in myocyte number; cell growth reduced by 52% the difference in the total number of myocytes present at 1 week between treated and untreated hearts ( Figure 8E and 8F) . The fraction of cycling myocytes and their mitotic index were 53% and 95% higher in treated than in control mice, respectively ( Figure 8G ).
Discussion
Findings in the current study indicate that the postnatal development of the heart is largely dependent on the generation of a myocyte progeny that is not present at birth but results from growth and differentiation of resident CSCs. Inhibition of this process by blockade of Notch signaling affects the increase in myocyte number and cardiac mass necessary to sustain the work load of the growing organism and the changes in the patterns of blood flow and peripheral resistance dictated by the switch from the fetal to the adult circulatory system. Preexisting myocytes undergo cellular hypertrophy, but this response cannot prevent the onset of a dilated myopathy and high mortality. These observations underscore the role that CSCs have in the physiological acquisition of the adult heart phenotype. The notion that myocyte hypertrophy alone is responsible for the maturation of the heart after birth 1 must be reconsidered. week on heart weight, myocyte number, volume, cross-sectional area (CSA), and length. Number of myocytes across the left ventricular (LV) wall and capillary density are also shown. C, Mortality rate after cessation of ␥-secretase inhibition. D through F, M-mode echocardiogram at 21 days, that is, 2 weeks after the last administration of the ␥-secretase inhibitor, together with fractional shortening, ejection fraction and chamber diameter (D). Cardiac anatomy, myocyte number, and volume (E and F) and the fraction of cycling and dividing myocytes (G) are also shown.
Plasticity of the Forming Myocardium
The developing heart is a dynamic organ in which myocyte hypertrophy, myocyte death, and, as shown in the present study, de novo formation of myocytes from differentiation of CSCs all contribute to the changes in cardiac size and shape that occur shortly after birth until myocardial loading has stabilized in the young adult organism. A significant fraction of myocytes expresses early in life the senescence-associated protein p16 INK4a and undergo apoptosis, suggesting that a subset of these cells has a rather short lifespan 13 and that myocyte renewal is an important regulatory process of cardiac maturation. Although interference with cardiomyogenesis by inhibition of the Notch pathway has a powerful negative effect on the structure and function of the growing heart, a similar mechanism is operative in adulthood and aging. Spontaneous mutations of the c-kit receptor with nearly 80% to 90% reduction in its tyrosine kinase activity 14 are coupled with a marked attenuation in the adaptation of the heart to ischemic myocardial injury. 15 Similarly, the aging myopathy typically shows loss of CSCs in animals and humans, 16, 17 and, in animal models, the aging cardiac phenotype may be rescued by delaying CSC senescence or activating the residual pool of functionally competent CSCs. 17, 18 In the present study, results in the neonatal heart by using a loss-of-function strategy strengthen the notion that the modulation of cardiac growth physiologically and pathologically is mediated by the ability of cardiomyocytes to hypertrophy but, most importantly, by the inherent capacity of CSCs to expand rapidly the myocyte pool. Activation and growth of CSCs increase the muscle compartment to degrees that cannot be achieved by cellular hypertrophy alone. 19, 20 The CSC is the regulatory cell that controls physiological hypertrophy and conditions pathological hypertrophy and cardiac failure.
CSCs expressing the stem cell antigen c-kit have previously been found in the neonatal mouse heart. 21, 22 From birth to 1 month of age, the increase in myocyte volume and the growth of the coronary vasculature lead to an apparent decline in the number of CSCs in the adult organ. 21, 22 However, the relative proportion of CSCs is rather constant: 1 CSC per 30 000 cells in animals 12 and humans. 23 This value is comparable to the frequency of hematopoietic stem cells (HSCs) in the bone marrow: 1 HSC per 10 000 to 100 000 cells. 24, 25 Additionally, hematopoietic markers have been identified in c-kit-positive CSCs, suggesting that HSCs migrate from the bone marrow to the heart, contributing to the formation of myocytes and coronary vessels. 22, 26 Our results do not support this possibility; CSCs are negative for CD34, CD45, and prominin, challenging the contribution of the bone marrow to the development of the mouse heart. Recently, unrealistic values of c-kit-positive HSCs (9%) and CSCs (0.5%) have been reported, 26 questioning the validity of the approach and interpretation of the data.
Notch1 and CSC Fate
Our in vitro and in vivo results indicate that the molecular pathway that controls the clonal formation of myocytes 3 and the transition from undifferentiated CSCs to amplifying myocytes involves primarily the activation of Notch1. The ability of Notch to modulate the developmental decision of progenitor cells is not unique to the heart. The Notch system is involved in cell fate specification by maintaining the stemness or favoring the commitment of primitive cells. 27 In the latter case, the function of Notch is restricted to 1 of the 2 steps involved in stem cell differentiation: the early phase of acquisition of a specific cell phenotype or the late phase of cell maturation. In analogy with the heart, skeletal muscle regeneration involves initially a Notch-dependent response in which the activation of satellite cells gives rise to a population of highly replicating intermediate progenitors that express myogenic proteins. 28 The transition from the proliferative to the quiescent state of maturing myotubes does not occur until Notch signaling is downregulated and the Wnt pathway sets in motion its downstream targets.
The relevance of Notch in the balance between cell proliferation and differentiation has been documented in the embryonic heart. 29 Notch1 controls the evolution from the primitive myocardial epithelium to the trabecular and compact myocardium. Prolonged Notch1 activation leads to excessive cardiomyocyte proliferation with formation of ectopic trabecular structures. 29 As shown in the present study, this effect of Notch1 persists after birth, and replicating myocytes derive from activation of CSCs and upregulation of Nkx2.5. However, it cannot be excluded that N1ICD-negative cardiomyocytes constitute a population of myocytes formed independently from differentiation of CSCs. Importantly, the expression of Notch1 in CSCs and the heterogeneity in the distribution of N1ICD and Nkx2.5 in replicating myocytes may reflect temporally regulated modulation of Notch1 signaling. This process may involve the transition from undifferentiated Notch1-positive CSCs to early committed N1ICD-positive myocytes and then to functionally competent N1ICD-negative maturing parenchymal cells.
Consistent with our observations, the proliferative state of immature cardiomyocytes in vivo has been shown to depend on sustained upregulation of the Notch pathway and the intracellular localization of the cytosolic and nuclear fragments of Notch1. 30 Replication of neonatal myocytes in vitro is enhanced by exposure to Jagged 1 and blocked by ␥-secretase inhibition, suggesting that these cells express Notch1. However, the presence of Notch1 on the myocyte membrane appears to be an in vitro phenomenon, as detected by us (not shown) and others. 30 N1ICD dictates the acquisition of the cardiomyocyte phenotype in EPCs, and this response is enhanced by coculture with neonatal myocytes secreting Jagged1. 31 Neonatal myocytes have Notch1 transcripts, but RT-PCR assay cannot distinguish between the extracellular and intracellular domains of the receptor, failing to prove that Notch1 is actually expressed on the sarcolemma. 31 In lower organisms, Notch inhibits cardiomyocyte formation and differentiation, whereas in mammals, Notch1 deletion results in myocardial hypoplasia. 32 These findings may indicate that Notch controls cardiogenesis at multiple stages, from the initial phase of mesoderm commitment to the final step of myocyte generation and maturation. 32, 33 Differences in Notch function probably are dependent on the involvement of different receptor isoforms and ligands, the cell in question, and the context and timing of the process.
Notch1, Nkx2.5, and Cardiomyogenesis
During embryonic development, the homeodomain factor Nkx2.5 occupies an upstream position in the hierarchy of the cardiac regulatory genes, driving directly or indirectly the expression of multiple genes involved in heart formation. 34 Homozygous Nkx2.5-null embryos are characterized by arrest of cardiac growth and death between 9.5 and 11.5 days of prenatal life 35 pointing to the essential role of Nkx2.5 in cardiac morphogenesis. However, chimeric embryos with variable contribution of Nkx2.5-null myocytes show that the severity of the cardiac abnormality is proportional to the fraction of Nkx2.5-null cells present in the developing heart. 34 The normal phenotype of chimeric hearts including 15% Nkx2.5-null cells suggests that the concomitant expression of Nkx2.5 in all myocytes is not required for the proper development of the heart. These findings are consistent with the progressive decrease in the number of Nkx2.5-positive myocytes from the embryonic to the adult heart shown in the present study and previously. 35 The heterogeneous distribution of Nkx2.5 is, however, in conflict with the notion that this transcription factor is indispensable for the maintenance of the differentiated state of cardiomyocytes. To reconcile these conflicting observations, the possibility has been raised that Nkx2.5 may promote the synthesis and secretion of paracrine factors that support the survival and the maturation of the surrounding embryonic myocytes. 34 A similar phenomenon may be operative in the neonatal and adult myocardium. Activation of the Notch1 receptor may transactivate directly the Nkx2.5 gene in a subset of CSCs promoting indirectly the commitment of adjacent primitive cells and preserving the terminally differentiated phenotype of neighboring adult cardiomyocytes. This mechanism may contribute to the control of cardiac homeostasis when old, dying cardiomyocytes are replaced by new cells that coexpress Nkx2.5 and the active fragment of Notch1. 5 Mutations of genes of the Notch system cause cardiac abnormalities in genetically engineered mice 32 and humans. 36 Notch signaling promotes the epithelial-to-mesenchymal transition that is crucial for the formation of valvular structures, 37 and alterations of Notch signaling in progenitor cells of the second heart field result in abnormalities of the aortic arch and outflow tract. 38 Because inhibition of Notch1 leads to the development of a dilated myopathy in neonatal mice, the hypothesis may be advanced that Notch1 is involved in the etiology of idiopathic dilated cardiomyopathy in children. Dilated cardiomyopathy is the most common cause for cardiac transplantation in children, but its etiology is unknown in Ϸ65% of cases. 39 Our findings raise the possibility that pediatric idiopathic dilated cardiomyopathy may involve defects of Notch1 in CSCs with severe attenuation in the generation of cardiomyocytes.
In conclusion, the Notch1 receptor and its ligand Jagged1 are critical determinants of the commitment of neonatal CSCs to the myocyte lineage, the generation of amplifying myocytes, and the formation of a differentiated progeny. Shortly after birth, cardiomyogenesis counteracts ongoing myocyte death and expands the pool of parenchymal cells in the growing organ, fundamental factors in the progressive maturation of the heart and the acquisition of the adult cardiac phenotype. When this cascade of events is altered, physiological cardiac hypertrophy is prevented, maladaptive processes ensue, and a life-threatening dilated myopathy supervenes.
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